APO Research
Talk to an analyst

APO RESEARCH · REPORT

α-blocker

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global α-blocker Market Outlook and Growth Opportunities 2026

21 December 2025198 pages

Choose your research edition.

Industry Researchα-blocker Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal α-blocker Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal α-blocker Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal α-blocker Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal α-blocker Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global α-blocker market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for α-blocker is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for α-blocker is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for α-blocker is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the α-blocker market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the α-blocker market include Teva Pharmaceutical, Sanofi, Jhonson and Johnson, Novartis, Merck, Eli Lilly, Pfizer, GSK and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global α-blocker market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of α-blocker and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents α-blocker sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the α-blocker market size, projected growth trends, production technologies, key applications, and end-use industries.

α-blocker Segment by Company

Teva Pharmaceutical

Sanofi

Jhonson and Johnson

Novartis

Merck

Eli Lilly

Pfizer

GSK

Bayer

Bristol-Myers Squibb

Astra Zeneca

α-blocker Segment by Type

Non-selective Antagonists

Selective Antagonists

α-blocker Segment by Application

Raynaud's Disease

Hypertension

Erectile Dysfunction

α-blocker Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global α-blocker status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions α-blocker market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify α-blocker significant trends, drivers, influence factors in global and regions.

6. To analyze α-blocker competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global α-blocker market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of α-blocker and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of α-blocker.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the α-blocker market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global α-blocker industry.

Chapter 3: Detailed analysis of α-blocker manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of α-blocker in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of α-blocker in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. α-blocker Industry Trends Table 2. α-blocker Industry Drivers Table 3. α-blocker Industry Opportunities and Challenges Table 4. α-blocker Industry Restraints Table 5. Global α-blocker Revenue by Company (US$ Million) & (2021-2026) Table 6. Global α-blocker Revenue Share by Company (2021-2026) Table 7. Global α-blocker Sales Volume by Company (k tons) & (2021-2026) Table 8. Global α-blocker Sales Volume Share by Company (2021-2026) Table 9. Global α-blocker Average Price (US$/ton) of Company (2021-2026) Table 10. Global α-blocker Company Ranking, (2024-2026) & (USD Million) Table 11. Global α-blocker Key Company Manufacturing Base & Headquarters Table 12. Global α-blocker Company, Product Type & Application Table 13. Global α-blocker Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global α-blocker by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Non-selective Antagonists Table 18. Significant Companies of Selective Antagonists Table 19. Global α-blocker Sales Volume by Type 2021 VS 2025 VS 2032 (k tons) Table 20. Global α-blocker Sales Volume by Type (2021-2026) & (k tons) Table 21. Global α-blocker Sales Volume by Type (2027-2032) & (k tons) Table 22. Global α-blocker Sales Volume Share by Type (2021-2026) Table 23. Global α-blocker Sales Volume Share by Type (2027-2032) Table 24. Global α-blocker Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global α-blocker Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global α-blocker Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global α-blocker Sales Value Share by Type (2021-2026) Table 28. Global α-blocker Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Raynaud's Disease Table 30. Significant Companies of Hypertension Table 31. Significant Companies of Erectile Dysfunction Table 32. Global α-blocker Sales Volume by Application 2021 VS 2025 VS 2032 (k tons) Table 33. Global α-blocker Sales Volume by Application (2021-2026) & (k tons) Table 34. Global α-blocker Sales Volume by Application (2027-2032) & (k tons) Table 35. Global α-blocker Sales Volume Share by Application (2021-2026) Table 36. Global α-blocker Sales Volume Share by Application (2027-2032) Table 37. Global α-blocker Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global α-blocker Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global α-blocker Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global α-blocker Sales Value Share by Application (2021-2026) Table 41. Global α-blocker Sales Value Share by Application (2027-2032) Table 42. Global α-blocker Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 43. Global α-blocker Sales by Region (2021-2026) & (k tons) Table 44. Global α-blocker Sales Market Share by Region (2021-2026) Table 45. Global α-blocker Sales by Region (2027-2032) & (k tons) Table 46. Global α-blocker Sales Market Share by Region (2027-2032) Table 47. Global α-blocker Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global α-blocker Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global α-blocker Sales Value Share by Region (2021-2026) Table 50. Global α-blocker Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global α-blocker Sales Value Share by Region (2027-2032) Table 52. Global α-blocker Market Average Price (US$/ton) by Region (2021-2026) Table 53. Global α-blocker Market Average Price (US$/ton) by Region (2027-2032) Table 54. Global α-blocker Sales by Country: 2021 VS 2025 VS 2032 (k tons) Table 55. Global α-blocker Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global α-blocker Sales by Country (2021-2026) & (k tons) Table 57. Global α-blocker Sales Market Share by Country (2021-2026) Table 58. Global α-blocker Sales by Country (2027-2032) & (k tons) Table 59. Global α-blocker Sales Market Share by Country (2027-2032) Table 60. Global α-blocker Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global α-blocker Sales Value Market Share by Country (2021-2026) Table 62. Global α-blocker Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global α-blocker Sales Value Market Share by Country (2027-2032) Table 64. Teva Pharmaceutical Company Information Table 65. Teva Pharmaceutical Business Overview Table 66. Teva Pharmaceutical α-blocker Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 67. Teva Pharmaceutical α-blocker Product Portfolio Table 68. Teva Pharmaceutical Recent Development Table 69. Sanofi Company Information Table 70. Sanofi Business Overview Table 71. Sanofi α-blocker Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 72. Sanofi α-blocker Product Portfolio Table 73. Sanofi Recent Development Table 74. Jhonson and Johnson Company Information Table 75. Jhonson and Johnson Business Overview Table 76. Jhonson and Johnson α-blocker Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 77. Jhonson and Johnson α-blocker Product Portfolio Table 78. Jhonson and Johnson Recent Development Table 79. Novartis Company Information Table 80. Novartis Business Overview Table 81. Novartis α-blocker Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 82. Novartis α-blocker Product Portfolio Table 83. Novartis Recent Development Table 84. Merck Company Information Table 85. Merck Business Overview Table 86. Merck α-blocker Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 87. Merck α-blocker Product Portfolio Table 88. Merck Recent Development Table 89. Eli Lilly Company Information Table 90. Eli Lilly Business Overview Table 91. Eli Lilly α-blocker Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 92. Eli Lilly α-blocker Product Portfolio Table 93. Eli Lilly Recent Development Table 94. Pfizer Company Information Table 95. Pfizer Business Overview Table 96. Pfizer α-blocker Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 97. Pfizer α-blocker Product Portfolio Table 98. Pfizer Recent Development Table 99. GSK Company Information Table 100. GSK Business Overview Table 101. GSK α-blocker Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 102. GSK α-blocker Product Portfolio Table 103. GSK Recent Development Table 104. Bayer Company Information Table 105. Bayer Business Overview Table 106. Bayer α-blocker Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 107. Bayer α-blocker Product Portfolio Table 108. Bayer Recent Development Table 109. Bristol-Myers Squibb Company Information Table 110. Bristol-Myers Squibb Business Overview Table 111. Bristol-Myers Squibb α-blocker Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 112. Bristol-Myers Squibb α-blocker Product Portfolio Table 113. Bristol-Myers Squibb Recent Development Table 114. Astra Zeneca Company Information Table 115. Astra Zeneca Business Overview Table 116. Astra Zeneca α-blocker Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 117. Astra Zeneca α-blocker Product Portfolio Table 118. Astra Zeneca Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. α-blocker Distributors List Table 122. α-blocker Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. α-blocker Product Image Figure 2. Global α-blocker Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global α-blocker Sales Value (2021-2032) & (US$ Million) Figure 4. Global α-blocker Sales (2021-2032) & (k tons) Figure 5. Global α-blocker Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global α-blocker Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Non-selective Antagonists Image Figure 10. Selective Antagonists Image Figure 11. Global α-blocker Sales Volume by Type (2021 VS 2025 VS 2032) & (k tons) Figure 12. Global α-blocker Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global α-blocker Sales Volume Share by Type (2021-2032) Figure 14. Global α-blocker Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global α-blocker Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global α-blocker Sales Value Share by Type (2021-2032) Figure 17. Raynaud's Disease Image Figure 18. Hypertension Image Figure 19. Erectile Dysfunction Image Figure 20. Global α-blocker Sales Volume by Application (2021 VS 2025 VS 2032) & (k tons) Figure 21. Global α-blocker Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global α-blocker Sales Volume Share by Application (2021-2032) Figure 23. Global α-blocker Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global α-blocker Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global α-blocker Sales Value Share by Application (2021-2032) Figure 26. Global α-blocker Sales by Region: 2021 VS 2025 VS 2032 (k tons) Figure 27. Global α-blocker Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global α-blocker Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global α-blocker Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America α-blocker Sales Value (2021-2032) & (US$ Million) Figure 31. North America α-blocker Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe α-blocker Sales Value (2021-2032) & (US$ Million) Figure 33. Europe α-blocker Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific α-blocker Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific α-blocker Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America α-blocker Sales Value (2021-2032) & (US$ Million) Figure 37. South America α-blocker Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa α-blocker Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa α-blocker Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt α-blocker Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt α-blocker Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt α-blocker Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. α-blocker Value Chain Figure 125. Manufacturing Cost Structure Figure 126. α-blocker Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Non-selective Antagonists
  • Selective Antagonists
Applications
  • Raynaud's Disease
  • Hypertension
  • Erectile Dysfunction
Companies covered
  • Teva Pharmaceutical
  • Sanofi
  • Jhonson and Johnson
  • Novartis
  • Merck
  • Eli Lilly
  • Pfizer
  • GSK
  • Bayer
  • Bristol-Myers Squibb
  • Astra Zeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global α-blocker Sales Value (2021-2032)
  4. 1.2.2 Global α-blocker Sales Volume (2021-2032)
  5. 1.2.3 Global α-blocker Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 α-blocker Market Dynamics
  1. 2.1 α-blocker Industry Trends
  2. 2.2 α-blocker Industry Drivers
  3. 2.3 α-blocker Industry Opportunities and Challenges
  4. 2.4 α-blocker Industry Restraints
3 α-blocker Market by Company
  1. 3.1 Global α-blocker Company Revenue Ranking in 2025
  2. 3.2 Global α-blocker Revenue by Company (2021-2026)
  3. 3.3 Global α-blocker Sales Volume by Company (2021-2026)
  4. 3.4 Global α-blocker Average Price by Company (2021-2026)
  5. 3.5 Global α-blocker Company Ranking (2024-2026)
  6. 3.6 Global α-blocker Company Manufacturing Base and Headquarters
  7. 3.7 Global α-blocker Company Product Type and Application
  8. 3.8 Global α-blocker Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global α-blocker Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 α-blocker Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 α-blocker Market by Type
  1. 4.1 α-blocker Type Introduction
  2. 4.1.1 Non-selective Antagonists
  3. 4.1.2 Selective Antagonists
  4. 4.2 Global α-blocker Sales Volume by Type
  5. 4.2.1 Global α-blocker Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global α-blocker Sales Volume by Type (2021-2032)
  7. 4.2.3 Global α-blocker Sales Volume Share by Type (2021-2032)
  8. 4.3 Global α-blocker Sales Value by Type
  9. 4.3.1 Global α-blocker Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global α-blocker Sales Value by Type (2021-2032)
  11. 4.3.3 Global α-blocker Sales Value Share by Type (2021-2032)
5 α-blocker Market by Application
  1. 5.1 α-blocker Application Introduction
  2. 5.1.1 Raynaud's Disease
  3. 5.1.2 Hypertension
  4. 5.1.3 Erectile Dysfunction
  5. 5.2 Global α-blocker Sales Volume by Application
  6. 5.2.1 Global α-blocker Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global α-blocker Sales Volume by Application (2021-2032)
  8. 5.2.3 Global α-blocker Sales Volume Share by Application (2021-2032)
  9. 5.3 Global α-blocker Sales Value by Application
  10. 5.3.1 Global α-blocker Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global α-blocker Sales Value by Application (2021-2032)
  12. 5.3.3 Global α-blocker Sales Value Share by Application (2021-2032)
6 α-blocker Regional Sales and Value Analysis
  1. 6.1 Global α-blocker Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global α-blocker Sales by Region (2021-2032)
  3. 6.2.1 Global α-blocker Sales by Region: 2021-2026
  4. 6.2.2 Global α-blocker Sales by Region (2027-2032)
  5. 6.3 Global α-blocker Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global α-blocker Sales Value by Region (2021-2032)
  7. 6.4.1 Global α-blocker Sales Value by Region: 2021-2026
  8. 6.4.2 Global α-blocker Sales Value by Region (2027-2032)
  9. 6.5 Global α-blocker Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America α-blocker Sales Value (2021-2032)
  12. 6.6.2 North America α-blocker Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe α-blocker Sales Value (2021-2032)
  15. 6.7.2 Europe α-blocker Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific α-blocker Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific α-blocker Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America α-blocker Sales Value (2021-2032)
  21. 6.9.2 South America α-blocker Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa α-blocker Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa α-blocker Sales Value Share by Country, 2025 VS 2032
7 α-blocker Country-level Sales and Value Analysis
  1. 7.1 Global α-blocker Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global α-blocker Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global α-blocker Sales by Country (2021-2032)
  4. 7.3.1 Global α-blocker Sales by Country (2021-2026)
  5. 7.3.2 Global α-blocker Sales by Country (2027-2032)
  6. 7.4 Global α-blocker Sales Value by Country (2021-2032)
  7. 7.4.1 Global α-blocker Sales Value by Country (2021-2026)
  8. 7.4.2 Global α-blocker Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA α-blocker Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA α-blocker Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA α-blocker Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada α-blocker Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada α-blocker Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada α-blocker Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico α-blocker Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico α-blocker Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico α-blocker Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany α-blocker Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany α-blocker Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany α-blocker Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France α-blocker Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France α-blocker Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France α-blocker Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. α-blocker Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. α-blocker Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. α-blocker Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy α-blocker Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy α-blocker Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy α-blocker Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain α-blocker Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain α-blocker Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain α-blocker Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia α-blocker Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia α-blocker Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia α-blocker Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands α-blocker Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands α-blocker Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands α-blocker Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries α-blocker Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries α-blocker Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries α-blocker Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China α-blocker Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China α-blocker Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China α-blocker Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan α-blocker Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan α-blocker Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan α-blocker Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea α-blocker Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea α-blocker Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea α-blocker Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India α-blocker Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India α-blocker Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India α-blocker Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia α-blocker Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia α-blocker Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia α-blocker Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia α-blocker Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia α-blocker Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia α-blocker Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil α-blocker Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil α-blocker Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil α-blocker Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina α-blocker Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina α-blocker Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina α-blocker Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile α-blocker Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile α-blocker Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile α-blocker Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia α-blocker Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia α-blocker Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia α-blocker Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru α-blocker Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru α-blocker Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru α-blocker Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia α-blocker Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia α-blocker Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia α-blocker Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel α-blocker Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel α-blocker Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel α-blocker Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE α-blocker Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE α-blocker Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE α-blocker Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey α-blocker Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey α-blocker Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey α-blocker Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran α-blocker Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran α-blocker Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran α-blocker Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt α-blocker Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt α-blocker Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt α-blocker Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical
  2. 8.1.1 Teva Pharmaceutical Company Information
  3. 8.1.2 Teva Pharmaceutical Business Overview
  4. 8.1.3 Teva Pharmaceutical α-blocker Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical α-blocker Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi α-blocker Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi α-blocker Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Jhonson and Johnson
  14. 8.3.1 Jhonson and Johnson Company Information
  15. 8.3.2 Jhonson and Johnson Business Overview
  16. 8.3.3 Jhonson and Johnson α-blocker Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Jhonson and Johnson α-blocker Product Portfolio
  18. 8.3.5 Jhonson and Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis α-blocker Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis α-blocker Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck α-blocker Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck α-blocker Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly α-blocker Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly α-blocker Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer α-blocker Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer α-blocker Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 GSK
  44. 8.8.1 GSK Company Information
  45. 8.8.2 GSK Business Overview
  46. 8.8.3 GSK α-blocker Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 GSK α-blocker Product Portfolio
  48. 8.8.5 GSK Recent Developments
  49. 8.9 Bayer
  50. 8.9.1 Bayer Company Information
  51. 8.9.2 Bayer Business Overview
  52. 8.9.3 Bayer α-blocker Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bayer α-blocker Product Portfolio
  54. 8.9.5 Bayer Recent Developments
  55. 8.10 Bristol-Myers Squibb
  56. 8.10.1 Bristol-Myers Squibb Company Information
  57. 8.10.2 Bristol-Myers Squibb Business Overview
  58. 8.10.3 Bristol-Myers Squibb α-blocker Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb α-blocker Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb Recent Developments
  61. 8.11 Astra Zeneca
  62. 8.11.1 Astra Zeneca Company Information
  63. 8.11.2 Astra Zeneca Business Overview
  64. 8.11.3 Astra Zeneca α-blocker Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Astra Zeneca α-blocker Product Portfolio
  66. 8.11.5 Astra Zeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 α-blocker Value Chain Analysis
  2. 9.1.1 α-blocker Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 α-blocker Sales Mode & Process
  6. 9.2 α-blocker Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 α-blocker Distributors
  9. 9.2.3 α-blocker Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst